An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

Europe's record-breaking June heatwave led to an estimated 10,000 excess deaths across 27 countries, with older adults accounting for the overwhelming majority of fatalities, according to official data.

Data published by EuroMOMO—a mortality monitoring network supported by the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO)—showed around 10,000 excess deaths during the week of June 22-28, when extreme heat peaked across France, Spain, Britain and several other European countries.

More than 9,000 of these deaths were among people aged 65 years and older.

"To have this kind of excess at this time of year is unusual. It's really high," Lasse Vestergaard, Chief Physician at Denmark's Statens Serum Institut, which hosts EuroMOMO, was quoted as saying to Reuters news agency.

"It is difficult to explain this high excess mortality by anything but the extreme heat," he added.

The figures are based on all-cause mortality, meaning they include deaths from all causes rather than only those officially classified as heat-related.

Scientists have also said the late-June heatwave would have been "virtually impossible" without human-caused climate change, which is making extreme heat events more frequent and intense.

England And Wales Saw 2,700 Heat-Related Deaths

A separate analysis by researchers from the London School of Hygiene & Tropical Medicine (LSHTM), Imperial College London, and the Met Office estimated more than 2,700 excess heat-related deaths during the May and June 2026 heatwaves in England and Wales.

Researchers estimated:

• Around 550 heat-related deaths occurred during the May 21-29 heatwave.
• Around 2,200 heat-related deaths occurred during the June 18-28 heatwave.

The study found that around 42% of the total heat-related deaths across both heatwaves were attributable to human-caused climate change.

Climate Change Intensified The Heat

According to the report, climate change increased daytime maximum temperatures across England and Wales by 3°C to 4°C.

The analysis estimated that climate change was responsible for:

• About 59% of heat-related deaths occurred during the May heatwave.
• Around 38% of heat-related deaths occurred during the June heatwave.

Both heatwaves shattered long-standing temperature records, with 35.1°C recorded in West London in May and 37°C in East Anglia in June.

"We are still in the first half of summer in the UK and large parts of England and Wales have already experienced two record-breaking heatwaves," said Dr Malcolm Mistry, Assistant Professor in Climate and Geo-spatial Modelling at LSHTM.

June 2026 Among The Hottest On Record

According to the Copernicus Climate Change Service (C3S), June 2026 was the hottest June ever recorded in western Europe and the second warmest globally.

The record temperatures were driven in part by the highest sea surface temperatures ever recorded for June.

"Heatwaves like this are what we expect to see in a changing climate," said John Kennedy, Head of Climate Information at the World Meteorological Organization (WMO).

He noted that Europe has warmed by around 2°C over the past 50 years, making it the world's fastest-warming continent and increasing the frequency of extreme heat events.

Why Extreme Heat Can Be Deadly

Extreme heat is often called the "silent killer" because heat-related deaths are frequently underreported. Globally, an estimated 489,000 people died from heat-related causes each year between 2000 and 2019, according to modeled estimates.

Heat stress develops when the body absorbs more heat than it can release. While sweating and increased blood flow to the skin normally help regulate body temperature, these cooling mechanisms become less effective during prolonged periods of intense heat—especially when humidity is high.

According to Lachlan McIver, Health Advisor at the WHO-WMO Climate and Health Joint Office, older adults, infants, pregnant women, outdoor workers, people experiencing homelessness, and those with chronic illnesses are at the greatest risk, although prolonged extreme heat can affect anyone.

In a breakthrough that could transform tuberculosis treatment (TB) in rural India, researchers from the Indian Council of Medical Research (ICMR) have demonstrated that drones can dramatically speed up the transport of TB samples, helping patients receive a diagnosis faster and significantly reducing the cost of treatment.

ICMR Uses Drones To Transport Patient Samples

Published recently in the International Journal of Tuberculosis and Lung Disease Open, the ICMR’s i-DRONE initiative is a pilot project conducted in Telangana’s Yadadri-Bhuvanagiri district.

The study is based on whether drones could transport sputum samples from remote health centres to TB diagnostic laboratories more efficiently than conventional road transport.

Researchers found that the turnaround time for TB diagnosis fell drastically from 15 days to just five days after drones were used to transport patients' sputum. The average time taken for diagnosis also dropped from 16.6 days to 6.9 days, helping patients seek TB treatment and care much earlier, which is a crucial factor in preventing disease progression and containing transmission.

The savings came primarily from eliminating repeated trips to distant diagnostic centres, reducing travel costs, wage losses, and other indirect expenses that often discourage people from seeking timely care.

The savings in patients’ costs primarily came from avoiding multiple trips to the diagnostic centres, wage losses, low travel costs, and other indirect expenses that often discourage patients from seeking timely care.

Also read: What Was The Pseudo-Tuberculosis Like 'Syndrome K' Saved Thousand Lives During World War II?

How Was The Study Conducted?

The year-long study is based on 840 patients, including 206 before the drone programme and 634 after its implementation. Instead of relying on road transport, healthcare workers collected sputum samples at the health facilities located in villages.

Drones then flew the samples directly to district TB laboratories, avoiding delays due to poor roads, difficult terrain, and limited public transport availability.

“The intervention demonstrated a significant reduction in the turnaround time and improved access to TB diagnosis in rural and remote Indian settings,” the researchers wrote.

The study also found that the speed of reporting improved substantially. Before drones were used, more than 90% of patients waited longer than two days to receive their test results. After the intervention, most patients received their reports within a day, allowing TB treatment to begin much sooner.

Bridging The Gap In Accessibility

Apart from faster diagnosis and low costs, researchers believe this technology could help overcome one of the biggest barriers to TB care - accessibility.

In several remote regions, patients often delay getting tested as travelling to district and city hospitals means losing a day’s wages, paying for transport, or arranging a family member to accompany them.

Drone transport takes away a significant part of that burden from patients. Healthcare workers who were interviewed during the project were also optimistic about using drone services and technology for other diseases beyond tuberculosis.

According to a companion feasibility study, many believed the same network and technology could eventually help transport blood samples, vaccines, medicines, and diagnostic specimens for other time-sensitive diseases.

The Democratic Republic of Congo (DRC) is battling its 17th Ebola outbreak, caused by the rare Bundibugyo strain, which has become the fastest-growing Ebola outbreak in the continent's history.

Declared on May 14, 2026, the outbreak has rapidly expanded, with 1,873 confirmed cases and 672 deaths reported across five provinces, according to the country's health authorities.

Unlike the more common Zaire strain of Ebola, the Bundibugyo strain currently has no approved vaccine or antiviral treatment.

Earlier this month, World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus announced the launch of a clinical trial evaluating two potential treatments.

"The PARTNERS trial will evaluate the monoclonal antibody MBP134 and the antiviral drug remdesivir, alone and in combination," he said.

Now, researchers have reached another major milestone. The first vaccine candidate targeting the Bundibugyo Ebola virus (BDBV)—developed by the University of Oxford and manufactured by the Serum Institute of India (SII) with support from the Coalition for Epidemic Preparedness Innovations (CEPI)—has entered Phase 1 human clinical trials.

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the study, which will evaluate the vaccine in healthy adult volunteers.

What Is The Chadox1 BDBV Vaccine?

Also read: Ebola Bundibugyo Strain: All You Should Know About The Rare Virus

The University of Oxford has developed an experimental vaccine candidate called ChAdOx1 BDBV, designed specifically to protect against the Bundibugyo strain of Ebola.

The vaccine uses the same ChAdOx1 viral vector platform that formed the basis of the Oxford-AstraZeneca COVID-19 vaccine. It is reportedly the first of four Bundibugyo Ebola vaccine candidates currently under development to enter human clinical trials.

How Does The Vaccine Work?

The vaccine uses a genetically modified chimpanzee adenovirus (ChAdOx1)—a harmless virus that normally causes the common cold in chimpanzees—as a delivery vehicle.

Scientists have inserted genetic material from the Ebola Bundibugyo virus into this harmless virus. Once injected in humans, the modified virus trains the immune system to recognize the Ebola virus and produce protective antibodies and fight the infection.

The vaccine has already shown promising results in mice and macaque monkeys and is being manufactured to clinical standards by the Serum Institute of India, which has already produced and stockpiled around 620,000 doses.

Based on the preclinical data, the UK's MHRA approved the vaccine to move into human trials.

Read More: Ebola Outbreak: The Unique Symptoms Seen In Patients Infected With Bundibugyo

ChAdOx1 BDBV Vaccine: Phase 1 human trial

The Oxford researchers will recruit 50 healthy adults aged 18 to 55 years in the UK for the Phase 1 trial, with the first doses expected to be administered within weeks.

Scientists are also working with partners in Uganda to prepare future clinical trials in Africa. Participants will be monitored for one year, although researchers expect to know much sooner whether the vaccine generates the desired immune response and whether any unexpected side effects occur.

"We're doing phase one (early stage) trials of new vaccines all of the time, precisely to be ready for exactly this kind of outbreak," Dr Katrina Pollock, the chief investigator of the trial at the University of Oxford, told the BBC.

Can A Single-dose Vaccine Work?

Researchers are also exploring preventive vaccination strategies for healthcare workers and people who have been in close contact with infected patients.

One such approach is ring vaccination, in which individuals surrounding a confirmed Ebola case are vaccinated or given preventive treatment to stop further spread.

The goal is to develop a single-dose vaccine, similar to the licensed vaccine against the Ebola Zaire strain.

Scientists believe that both antibodies and T cells—immune cells that recognize and destroy infected cells—will play an important role in protection, although long-term immunity against the Bundibugyo strain is not yet fully understood.

"Pre-clinical models for these pathogens have already shown that a single-dose vaccine can protect animals. So, we are optimistic that a one-shot vaccine is achievable," Prof Teresa Lambe, Head of Vaccine Immunology, Oxford Vaccine Group, Pandemic Sciences Institute, University of Oxford, told The Indian Express.